0RD1 Stock Chart & Stats
kr616.00
kr5.00(0.81%)
At close: 4:00 PM EDT
kr616.00
kr5.00(0.81%)
Day’s Range― - ―
52-Week Rangekr433.00 - kr749.00
Previous CloseN/A
Volume231.00
Average Volume (3M)9.29K
Market Cap
kr37.40B
Enterprise Valuekr29.70K
Total Cash (Recent Filing)kr4.07B
Total Debt (Recent Filing)kr108.40M
Price to Earnings (P/E)54.2
Beta0.91
Next Earnings
Nov 05, 2026EPS Estimate
4.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.39
Shares Outstanding60,559,185
10 Day Avg. Volume4,248
30 Day Avg. Volume9,293
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)8.62
Price to Sales (P/S)16.11
P/FCF Ratio49.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr830.00Price Target Upside34.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)15.22
Revenue Forecast (FY)kr2.82B
Bulls Say, Bears Say
Bulls Say
High Profitability And MarginsSustained extremely high gross and operating margins indicate durable unit economics and strong pricing or manufacturing leverage. Such margin profile supports reinvestment in commercial expansion and pipeline, and provides resilience to cost shocks while enabling attractive cash conversion over a multi‑quarter horizon.
Strong Balance Sheet And CashA net cash position and effectively zero leverage provide strategic optionality: ability to fund SEK 200m commercial and SEK 150m R&D plans internally, absorb regulatory timing delays, and invest in manufacturing redundancy without immediate external financing, strengthening long‑term execution capacity.
Validated Platform & Pipeline CatalystsExternal partner validation (Lilly) and multiple upcoming clinical readouts materially derisk platform adoption and create recurring licensing/royalty upside. Successful pipeline milestones would broaden addressable markets and deepen platform monetization beyond direct product sales over coming quarters.
Bears Say
Regulatory / Manufacturing Timing RiskA manufacturing‑related CRL creates uncertain U.S. approval timing and a high probability of further inspections. Delays to Oclaiz/CAM2029 approvals can postpone sizable U.S. revenue and royalty streams, compress projected cash flows and require sustained cash burn for commercial readiness until resolution.
Weakening Free Cash Flow MomentumA near‑20% decline in FCF growth signals rising reinvestment and working capital absorption. While absolute cash generation remains strong, the deterioration reduces the margin of safety for funding launches, manufacturing redundancy and pipeline investments, increasing sensitivity to operational setbacks.
Rising Commercial Spend & Execution RiskAggressive commercial scale‑up increases fixed cost base and execution risk outside core markets. Higher SG&A and planned incremental spend elevate breakeven on new launches and make near‑term margins and cash conversion more sensitive to uptake rates and conversion timelines in key markets like the U.S.
Camurus AB News
0RD1 FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest share price was kr433.00 and its highest was kr749.00 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr37.40B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Nov 05, 2026 which is in 92 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Jul 15, 2026. The company reported kr4.065 earnings per share for the quarter, beating the consensus estimate of kr3.227 by kr0.838.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of N/A. See more information on Camurus AB dividends here
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 4.07.
How many shares outstanding does Camurus AB have?
Camurus AB has 60,559,185 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr4.065 in its last earnings report, beating expectations of kr3.227. Following the earnings report the stock price went up 14.639%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in GB:0RD1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
0RD1 Company Deck
0RD1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and financial picture: record product sales, broad‑based Buvidal growth, accelerating U.S. Brixadi royalties, improving underlying revenue CAGR (~21%), strong profitability (42% margin) and a robust cash position (SEK 4.1 billion). Pipeline momentum is substantial with SORENTO nearing primary analysis, CAM2056 advancing, positive POSITANO data and an expanded Lilly collaboration. Key negatives center on a manufacturing‑related FDA Complete Response Letter for the U.S. CAM2029 filing, short‑term working capital and investment outflows, increased SG&A as commercial scale‑up continues, and market/capacity constraints in Australia. Overall, the positives (record sales, revenue growth, strong cash and multiple near‑term pipeline catalysts) outweigh the material but addressable regulatory and operational risks.View all GB:0RD1 earnings summaries0RD1 Stock 12 Month Forecast
Average Price Target
kr830.00
▲(34.74% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―